PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.69
Both companies show negative D/E. Martin Whitman would investigate if industry distress creates special situation opportunities.
2.47
Much higher net debt at 1.25-1.5x RVPH's 1.70. Bill Ackman would demand clear deleveraging catalysts.
-1.27
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
0.01
Current ratio below 50% of RVPH's 0.90. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.